LENANGIO 25 MG

About

Lenalidomide is an immunomodulatory drug primarily used in the treatment of various hematological malignancies. It exerts its therapeutic effects through multiple mechanisms, including direct anti-tumor activity, inhibition of angiogenesis, and modulation of the immune system. Specifically, it enhances T-cell and natural killer (NK) cell activity, inhibits pro-inflammatory cytokine production, and induces apoptosis in malignant cells. It is particularly effective in conditions like multiple myeloma and myelodysplastic syndromes, where it can improve erythroid responses and reduce transfusion dependence. Its precise molecular targets involve cereblon, a component of an E3 ubiquitin ligase complex, leading to the degradation of specific transcription factors crucial for cancer cell survival and proliferation.

Uses

• Multiple Myeloma
• Myelodysplastic Syndromes (MDS) with del(5q)
• Mantle Cell Lymphoma (MCL)
• Follicular Lymphoma (FL)

Directions For Use

Take orally once daily, with or without food, as prescribed by your physician. Swallow the capsule whole with water.

Benefits

• Effective in treating hematological cancers.
• Improves overall survival in multiple myeloma.
• Reduces transfusion dependence in MDS.
• Modulates the immune system for anti-tumor effects.
• Convenient oral administration.
• Well-established efficacy in relapsed/refractory settings.

Side Effects

• Myelosuppression (neutropenia, thrombocytopenia)
• Fatigue
• Diarrhea
• Rash
• Peripheral neuropathy
• Deep vein thrombosis
• Pulmonary embolism
• Muscle cramps
• Fever
• Nausea
• Constipation
• Dizziness

Safety Measures

• Alcohol - Avoid or limit alcohol consumption due to potential for increased side effects and liver strain.
• Pregnancy - Category X; highly teratogenic. Strict contraception is mandatory for both male and female patients.
• Breastfeeding - Not recommended during treatment due to potential for serious adverse effects in the breastfed infant.
• Liver - Use with caution; dose adjustment may be necessary in patients with severe hepatic impairment.
• Kidney - Dose adjustment is required based on creatinine clearance; close monitoring is essential.
• Lung - Monitor for signs of pulmonary events, including interstitial lung disease or pulmonary hypertension.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.